Objective and subjective outcomes following implantable collamer lens (ICL) implantation for the correction of myopia

植入式胶原蛋白晶体(ICL)矫正近视后的客观和主观结果

阅读:1

Abstract

BACKGROUND: Implantable collamer lens (ICL) implantation has gained popularity as a surgical option for the correction of high myopia. This study aimed to evaluate the visual outcomes, patient satisfaction, and safety of ICL implantation by combining objective and subjective parameters for a comprehensive assessment. METHODS: This prospective, interventional study included 67 eyes from 37 patients who underwent ICL implantation. Visual acuity, refractive outcomes, anterior chamber depth, ICL vault, endothelial cell density, intraocular pressure, and patient satisfaction using the Visual Function Questionnaire-25 (VFQ-25) were assessed preoperatively and at various postoperative time points up to 12 months. RESULTS: At 12 months postoperatively, the mean uncorrected distance visual acuity improved to 0.10 ± 0.08 LogMAR, and the mean corrected distance visual acuity improved to 0.04 ± 0.05 LogMAR. The mean spherical equivalent decreased from -10.57 ± 2.22 D preoperatively to -0.10 ± 0.25 D, with 95.5% of eyes within ±0.50 D of the target refraction. The mean ICL vault was stable at 625 ± 80 μm, and no significant endothelial cell loss or complications were observed. The mean composite VFQ-25 score improved significantly from 72.87 ± 11.23 preoperatively to 93.39 ± 4.68 at 12 months postoperatively (P < 0.001). CONCLUSION: This study demonstrates that ICL implantation is a safe, effective, and predictable option for the correction of high myopia, providing excellent visual outcomes, refractive stability, and significant improvements in patient satisfaction and quality of life. The combination of objective and subjective parameters provides a comprehensive assessment of surgical success and patient-reported outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。